Skip to Content

Tobramycin Sulfate Injection

Last Updated: December 1, 2018
Status: Current

Products Affected - Description
    • Tobramycin Sulfate solution for injection, Akorn, 40 mg/mL, 2 mL vial, 25 count, NDC 17478-0114-02
    • Tobramycin Sulfate solution for injection, Akorn, 40 mg/mL, 30 mL vial, 1 count, NDC 17478-0114-30
    • Tobramycin Sulfate solution for injection, Baxter (formerly Claris), 40 mg/mL, 2 mL vial, 25 count, NDC 36000-0244-25
    • Tobramycin Sulfate solution for injection, Baxter (formerly Claris), 40 mg/mL, 30 mL vial, 1 count, NDC 36000-0242-01
    • Tobramycin Sulfate lyophilized powder for solution for injection, Fresenius Kabi, 1.2 gram, 50 mL preservative-free vial, 6 count, NDC 63323-0303-51
    • Tobramycin Sulfate solution for injection, Fresenius Kabi, 10 mg/mL, 2 mL vial, 25 count, NDC 63323-0305-02
    • Tobramycin Sulfate solution for injection, Fresenius Kabi, 40 mg/mL, 2 mL vial, 25 count, NDC 63323-0306-02
    • Tobramycin Sulfate solution for injection, Fresenius Kabi, 40 mg/mL, 30 mL vial, 10 count, NDC 63323-0306-30
    • Tobramycin Sulfate solution for injection, Mylan Institutional, 40 mg/mL, 2 mL vial, 25 count, NDC 67457-0473-22
    • Tobramycin Sulfate solution for injection, Pfizer, 40 mg/mL, 2 mL vial, 25 count, NDC 00409-3578-01
    • Tobramycin Sulfate solution for injection, Teva, 40 mg/mL, 2 mL vial, 25 count, NDC 00703-9402-04
    • Tobramycin Sulfate solution for injection, Teva, 40 mg/mL, 30 mL vial, 1 count, NDC 00703-9416-01
Reason for the Shortage
    • Akorn has tobramycin injection on shortage due to manufacturing delays.
    • Pfizer has tobramycin injection on shortage due to manufacturing delays.
    • Teva discontinued tobramycin 40 mg/mL 30 mL vials in June 2018.
Available Products
    • Tobramycin Sulfate solution for injection, Fresenius Kabi, 40 mg/mL, 50 mL vial, 1 count, NDC 63323-0307-51
    • Tobramycin Sulfate solution for injection, Mylan Institutional, 40 mg/mL, 30 mL vial, 10 count, NDC 67457-0428-30
    • Tobramycin Sulfate lyophilized powder for solution for injection, X-Gen, 1.2 gram, 50 mL preservative-free vial, 1 count, NDC 39822-0412-01
    • Tobramycin Sulfate lyophilized powder for solution for injection, X-Gen, 1.2 gram, 50 mL preservative-free vial, 6 count, NDC 39822-0412-06

Estimated Resupply Dates

    • Akorn has tobramycin 40 mg/mL 2 mL and 30 mL vials on back order and the company cannot estimate a release date.
    • Baxter (formerly Claris) has tobramycin 40 mg/mL 2 mL and 30 mL vials on back order and the company cannot estimate a release date.
    • Fresenius Kabi has tobramycin 40 mg/mL 2 mL vials on back order and the company estimates a release date of mid-December 2018. The 10 mg/mL 2 mL vials are on back order and the company estimates a release date of late-December 2018. The tobramycin 1.2 gram preservative-free 50 mL vials are on back order and the company estimates a release date of mid-December 2018. There are short-dated 40 mg/mL 30 mL vials with an expiration date of <2 months.
    • Mylan Institutional has tobramycin 40 mg/mL 2 mL vials on back order and the company cannot estimate a release date.
    • Pfizer has tobramycin 40 mg/mL 2 mL vials on back order and the company estimates a release date of January 2019.
    • Teva has temporarily discontinued tobramycin 40 mg/mL 2 mL vials.

Updated

Updated December 1, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 28, 2010 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide